1. Home
  2. ELVN vs VVX Comparison

ELVN vs VVX Comparison

Compare ELVN & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • VVX
  • Stock Information
  • Founded
  • ELVN 2016
  • VVX 2014
  • Country
  • ELVN United States
  • VVX United States
  • Employees
  • ELVN N/A
  • VVX N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • VVX Diversified Commercial Services
  • Sector
  • ELVN Health Care
  • VVX Consumer Discretionary
  • Exchange
  • ELVN Nasdaq
  • VVX Nasdaq
  • Market Cap
  • ELVN 1.2B
  • VVX 1.4B
  • IPO Year
  • ELVN 2020
  • VVX 2014
  • Fundamental
  • Price
  • ELVN $20.73
  • VVX $49.04
  • Analyst Decision
  • ELVN Strong Buy
  • VVX Buy
  • Analyst Count
  • ELVN 5
  • VVX 9
  • Target Price
  • ELVN $41.20
  • VVX $64.11
  • AVG Volume (30 Days)
  • ELVN 747.2K
  • VVX 241.6K
  • Earning Date
  • ELVN 08-12-2025
  • VVX 08-05-2025
  • Dividend Yield
  • ELVN N/A
  • VVX N/A
  • EPS Growth
  • ELVN N/A
  • VVX N/A
  • EPS
  • ELVN N/A
  • VVX 1.29
  • Revenue
  • ELVN N/A
  • VVX $4,327,514,000.00
  • Revenue This Year
  • ELVN N/A
  • VVX $4.02
  • Revenue Next Year
  • ELVN N/A
  • VVX $4.80
  • P/E Ratio
  • ELVN N/A
  • VVX $38.33
  • Revenue Growth
  • ELVN N/A
  • VVX 7.38
  • 52 Week Low
  • ELVN $13.30
  • VVX $41.08
  • 52 Week High
  • ELVN $30.03
  • VVX $69.75
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 52.08
  • VVX 65.78
  • Support Level
  • ELVN $19.22
  • VVX $47.73
  • Resistance Level
  • ELVN $21.90
  • VVX $49.73
  • Average True Range (ATR)
  • ELVN 1.49
  • VVX 1.28
  • MACD
  • ELVN -0.19
  • VVX 0.58
  • Stochastic Oscillator
  • ELVN 39.43
  • VVX 86.58

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: